Flexible Manufacturing
Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson's.
Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson’s.
Zambon s.p.A. entrusted Catalent as its partner for timely development and launch of Safinamide under the brand name Xadago® to a worldwide target market.
Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
Product enquiry
Thank you for submitting the form. Your enquiry will be submitted to the company.